Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
Obesity · 2025
DOI: 10.1002/oby.24202 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2025. Written by Beverly G Tchang and 5 co-authors. Institution: Weill Cornell Medicine, New York, New York, USA. Major MEDLINE topics: Antihypertensive Agents, Glucagon-Like Peptides, Hypertension, Hypolipidemic Agents. Cited 9 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novo Nordisk, Novo Nordisk Inc..
Abstract (original language)
Objective
The objective of this study was to assess antihypertensive and lipid‐lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.
Methods
Efficacy and safety of semaglutide 2.4 mg were evaluated in the STEP clinical trials. In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis. Changes in antihypertensive or lipid‐lowering treatment intensity from randomization to end of treatment were evaluated.
Results
In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid‐lowering treatment intensity reduction by end of treatment. A smaller proportion underwent antihypertensive or lipid‐lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo. In participants receiving antihypertensive or lipid‐lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo.
Conclusions
These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid‐lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification. image
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Weill Cornell Medicine, New York, New York, USA.
- The George Washington University, Washington, DC, USA.
- Novo Nordisk A/S, Søborg, Denmark.
- University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
- Novo Nordisk Inc., Plainsboro, New Jersey, USA.
ORCID profiles: Beverly G Tchang
Funding
- Novo Nordisk
- Novo Nordisk Inc.
Cite
APA
Tchang, B. G., Knight, M. G., Adelborg, K., Clements, J. N., Iversen, A. T., & Traina, A. (2025). Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials. Obesity. https://doi.org/10.1002/oby.24202
Vancouver
Tchang BG, Knight MG, Adelborg K, Clements JN, Iversen AT, Traina A. Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials. Obesity. 2025. doi:10.1002/oby.24202
BibTeX
@article{Tchang2025,
author = {Tchang, Beverly G and Knight, Michael G and Adelborg, Kasper and Clements, Jennifer N and Iversen, Aske Thorn and Traina, Andrea},
title = {Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24202}
}
EUVIMED